General discussion, page-1001

Hiall. It has been a great week. I am confident this is only the start. I thoughtit was a good time to consolidate some information for existing and newshareholders. If I get a positive response from readers I might start a newthread “Business Progress” or “New Shareholders” or otherwise I leave it herein general discussion. I want to give potential new shareholders a goodunderstanding of the business on their first look.

KEYBUSINESS MARKERS – Since last post ((last post listed at the bottom)).

Branding

• Name change – “Impression Healthcare Limited” now “Incannex Healthcare Limited” new website imminent – keep an eye on www.incannex.com.au

Oilsand Revenue

• CBD Oils – Record quarterly sales - $671k ((massive)) - Growth predicted to continue. https://hotcopper.com.au/documentembed?id=uOMxKKzFkiWRTLKhOROKAxjvSTYP5wq9yxKZqf91ke92GA%3D%3D
• CBD pressurised metered dose inhalers – Will be sold as an additional “value add” to the oils business.

ClinicalTrials

• IHL-675A Sepsis associated ARDS– Incannex has commenced its first clinical trial, being the animal study for its sepsis associated acute respiratory distress syndrome (‘SAARDS’) program. Results predicted to be released this week. https://hotcopper.com.au/documentembed?id=uOMxKKzFkiWRTLKhOROKAxjvSTYP5wy%2ByBSZqf91ke92GA%3D%3D
• IHL-42X Obstructive Sleep Apnoea (‘OSA’) – Incannex Partners with The Alfred and Novotech. Update last week - https://hotcopper.com.au/documentembed?id=uOMxKKzFkiWRTLKhOROKAxjvSTYP5wq5yhiZqf91ke92GA%3D%3D
• IHL-216A for the treatment of Traumatic Brain Injury and Concussion (‘TBI’) - focus on MMA baseline neurocognitive tests to be completed near future.
• Positive response to FDA approval pathway for ARDS, Sleep Apnoea and TBI.

Board& Appointments

• Board consistent with messaging and delivering to promises.
• Professor Terence O’Brien added to the team as Principal Investigator to assist Dr Mark Bleackley.

SHAREREGISTER

• Still very tightly held. With very little volume available to buy.

SHAREPRICE

• On the rise and the chart looks very promising. No sell volume. Good luck finding stock.

SUMMARY

• 1 quarter away from confirming they are a world leading oils and additional CBD solutions business. My current valuation today is 150mil or 20c.
• 1 x positive clinical trial adds “Billions” to valuation. Feedback arrives this week on our first clinical trial “ARDS”. Positive results send the valuation north very quickly.
• + we have multiple clinical trials in the pipeline. All well researched and evaluated.

PREVIOSULY POSTED 1+ MONTH AGO

ANNOUNCEMENTS

• James Grahame has joined the TBI program – this appointment ties in well with previous announcement of Liam Picken to advisory board. Tick to NRL & AFL.
• Appointment of Chief Scientific Officer – Dr Mark Bleackley – Hired Mark Bleackley for experience in clinical trial design.
• 1000 Patients for Incannex CBD-100 Oils – Month on month revenue increase. Procurement plans in place to improve margin. Strong relationship with Cannvalate. ((since announced "significant revenue growth" - market has not valued this in))

• CBD pressurised metered dose inhalers – First of a kind into Aus. Update due.
• Development of IHL-675A investigating for potential treatment of sepsis associated ARDS, leading cause of mortality from COVID-19 and other infections – trails to commence in Taiwan. ((have since commenced - results 4-6 weeks away))
• Positive response to FDA approval pathway for both Sleep Apnoea and TBI.

BUSINESSUPDATE

• Obstructive Sleep Apnoea (‘OSA’) - Specific formulation development of IHL-42X with a qualified pharmaceutical chemist was announced at the start of the year. Trial protocol is complete and first patients sourced. Commencement planned for Q2.
• IHL-216A for the treatment of Traumatic Brain Injury and Concussion (‘TBI’) - focus on MMA baseline neurocognitive tests to be completed near future.

COVIDIMPACT

• Matchday sales would be down, adjustments to business structure to reduce costs was already implemented leading into COVID. Business now low cost, limited resources spent on it and sales a bonus. ((since announced business will cease trading))

MC& OPTIONS

• MC seems low compared to peers. Seems cheap.
• Options expire in September – these will be in the money and will add 10m funds to the bank.

EXPANSION

• 2 clinical trials, in-halers, ARDS & month on month sales increase in oils.

SHAREREGISTER

• Tightly held register of directors & management.